NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policy2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury
About This Grant
Summary: Nitrogen mustard (NM), a potent cytotoxic vesicant, can cause acute lung injury and potentially lead to chronic conditions like fibrosis, emphysema, and bronchiolitis obliterans. NM remains a significant chemical threat due to its ease of synthesis and weaponization. Currently, there are no effective medical countermeasures to mitigate NM-induced lung damage, therefore, the search for an effective therapeutic or prophylactic treatment persists. The endocannabinoids and their lipid-related mediators contribute to the modulation of oxidative stress and lipid peroxidation and 2- Arachidonoylglycerol (2-AG), is the most abundant endocannabinoid. 2-AG is produced ‘on demand’ and rapidly degraded, and monoacylglycerol lipase (MAGL or MgII) is the main enzyme responsible for 2-AG catabolism. The hydrolysis of 2-AG by MAGL terminates the activation of CB receptors, releasing free AA that serves as a precursor for the synthesis of pro-inflammatory eicosanoids. Enhancing the 2-AG signaling displays an anti-inflammatory response to proinflammatory and mechanical insults. Our preliminary findings indicated that acute exposure to NM resulted in a significant increase in MAGL in mouse lung tissues, immune cells, and human alveolar macrophages. Furthermore, our pilot study showed that the administration of JZL184, a potent inhibitor of MAGL resulted in a significant reduction in NM-induced acute lung injury and immune cell infiltration in mice. Given these promising indications, this project aims to further investigate how augmenting the 2-AG signaling by inactivation of MAGL could confer protection against NM-induced lung injury. Aim 1: To assess the efficacy of MAGL inhibition/inactivation in protection against NM-induced acute lung injury, inflammatory response, and oxidative stress. Aim 2: To delineate the mechanism of protection by MAGL inhibition/inactivation in NM-induced acute lung injury, inflammatory response, and oxidative stress. These efforts would assist in translational strategies for the development of therapeutic agents against NM-induced lung damage.
Grant Summary
2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury is a OD - NIH Office of the Director grant providing up to $458K for university, nonprofit, healthcare org. Applications are due 2028-06-22 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $458K
2028-06-22
- 1Confirm your organization is eligible for 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury from OD - NIH Office of the Director, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to OD - NIH Office of the Director before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against OD - NIH Office of the Director's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury: Frequently Asked Questions
Who is eligible for the 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury?
2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury is offered by OD - NIH Office of the Director and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury provide?
2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury provides up to $458K per award from OD - NIH Office of the Director. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury deadline?
Applications for 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury are due 2028-06-22 (open). Because deadlines can change, verify the date with the funder, OD - NIH Office of the Director, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury?
To apply for 2-Arachidonoylglycerol signaling in nitrogen mustard-induced lung injury, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from OD - NIH Office of the Director.